Clinical Study on Facial Rejuvenation of Non-crosslinked Small Molecule Hyaluronic Acid Combined with Filorga NCTF®BOOST135 HA  

作　　者：He LIU Qin-bao HU Qiang YUAN 

机构地区：[1]Department of Medical Beauty,Beijing Sixth Hospital,Beijing City.100007,China [2]Gansu Vaccine Engineering Technology Research Center of Lanzhou Institute of Biological Products Co.,Ltd.,Lanzhou City,Gansu Province,730046,China

出　　处：《Chinese Journal of Plastic and Reconstructive Surgery》2019年第3期46-50,共5页

摘　　要：Objective To observe the clinical application of non-crosslinked small molecule hyaluronic acid combined with Filorga NCTF®BOOST135HA in facial rejuvenation.Methods A total of 156 patients were selected from the outpatient department of our department from January 2017 to January 2018,including 36 males and 120 females.They were randomly divided into treatment group(82 cases)and control group(74 cases).The age of the treatment group was 25-50 years old,with an average age of 34 years old,while that of the control group was 26-48 years old,with an average age of 35 years old.group A was treated with non-crosslinked small molecule hyaluronic acid combined with Filorga NCTF®BOOST135 HA,while group B was treated with non-crosslinked small molecule hyaluronic acid alone.Through two methods,the facial skin state is analyzed and the therapeutic effect is evaluated.Results Follow-up for 3-6 months after treatment showed that 73 cases were satisfied and 9 cases were not satisfied in group A,with a satisfaction rate of 89.02%.In group B,52 cases were satisfied and 22 cases were dissatisfied,with a satisfaction rate of 70.27%.Conclusion Hyaluronic acid combined with Filorga NCTF®BOOST135 HA is better than hyaluronic acid alone in the treatment of facial rejuvenation,and patients obtain higher satisfaction.

关 键 词：Non-crosslinked small molecule hyaluronic acid Filorga NCTF®BOOST135 HA Electronic syringe 

分 类 号：R62[医药卫生—整形外科]